In this segment focused on advanced renal cell carcinoma, Dr. Geynisman shifts the discussion to patients with intermediate and poor risk disease based on IMDC criteria and how this influences first-line treatment selection. Dr. McGregor and Dr. Wulff discuss how NCCN recommendations support both IO-IO and IO-TKI combinations in this population, while emphasizing that clinical context often guides the final decision.